Cagrilintide

5mg · Lyophilized Powder

Cagrilintide is a long-acting acylated analogue of amylin — the pancreatic hormone co-secreted with insulin at mealtimes — with a half-life of approximately 7–8 days enabling once-weekly dosing. It activates central amylin receptors in the area postrema and hindbrain to promote satiety, slow gastric emptying, and reduce food intake independent of the GLP-1 pathway. In Phase 2 trials at 4.5 mg weekly, cagrilintide produced approximately 10.8% body weight reduction over 26 weeks. When combined with semaglutide 2.4 mg in Phase 3 REDEFINE trials, the combination produced approximately 20% weight loss at 68 weeks — exceeding either agent alone.

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.